The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...